Loading clinical trials...

COMPLETED

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)

A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and Other Clinical Outcome Assessments of Parkinson's Disease Patients Treated With XADAGO (Safinamide)Tablets

NCT03944785•Supernus Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase IV, prospective, observational, post-marketing study designed to obtain additional data on the effect of XADAGO on motor and non-motor symptoms in Parkinson's Disease patients newly prescribed XADAGO.

Detailed Description

This Phase IV, multicenter, prospective, observational study to evaluate clinician-reported outcomes and patient-reported outcomes related to motor and non-motor symptoms, health status, quality of life and treatment satisfaction in PD patients who have been newly prescribed XADAGO according to Package Insert indication. This study also will gather "real world" data from a PD population in the US regarding their overall experience and degree of satisfaction with the use of XADAGO as an add-on treatment to their L-dopa regimen. Treatment experience will be captured using patient self-rating assessments as well as clinician ratings on assessments.

Eligibility

Age

30 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patient (and Care Partner, if required per Inclusion Criterion 6) is able to understand and provide signed informed consent and HIPAA authorization in English.
•2. Patient with diagnosis of idiopathic PD (all stages).
•3. Independent of the study, clinician's and patient's choice of treatment is XADAGO in accordance with the Package Insert indication.
•4. Patient is willing and able to participate in the study and complete study-related assessments for 2 months and, patients can continue for an optional 4-month study extension.
•5. Patient has access to an electronic device for the interim completion of PROs.
•6. Patient has an available Care Partner who is able and willing to assist with clinic attendance and completion of study assessments (e.g., PROs, health outcomes, etc.), if in the PI's opinion, assistance is needed to comply with all study visits and procedures.

Exclusion Criteria

•1. Any of the warnings, precautions, or contraindications listed in the XADAGO Package Insert that in the opinion of the PI would prevent appropriate treatment with XADAGO or impair study participation (e.g., pregnancy, lactation, severe hepatic impairment, etc.).
•2. Participation in any other clinical trial of an investigational drug or device within 4 weeks prior to the Baseline Visit or at any time during the study.
•3. Patient is currently receiving chemotherapy or radiation for any form of cancer (if history of cancer, must be in clinical remission at study entry) or currently receiving immunotherapy.
•4. Patients with conditions that are likely to prevent them from accurately and reliably completing study assessments, including evidence of moderate or severe dementia as determined by the clinician (not to include mild cognitive impairment \[MCI\]); major psychiatric illness (specifically diagnosis of schizophrenia, bipolar disorder or a history of attempted suicide); and/or severe and progressive medical illness (including terminal cancer, end-stage renal disease +/- undergoing dialysis).
•5. Severe or unpredictable dyskinesia at the time of the Baseline Visit.
•6. Previous participation in this study; a patient may not re-enroll after prior discontinuation or completion

Locations (30)

Alabama Neurology Associates

Homewood, Alabama, United States

Movement Disorders Neurology, Inc.

Bakersfield, California, United States

B.E.S.T. Center of Orange County

Laguna Hills, California, United States

Valley Parkinson Clinic

Los Gatos, California, United States

UC Davis Medical Center

Sacramento, California, United States

Hartford Healthcare

Vernon, Connecticut, United States

Georgetown University Hospital

Washington D.C., District of Columbia, United States

Parkinson's Disease and Movement Disorders Center of Boca Raton

Boca Raton, Florida, United States

Neuron Research

Naples, Florida, United States

Parkinson's Disease Treatment Center of SW Florida

Port Charlotte, Florida, United States

Key Dates

Start Date

November 30, 2017

Primary Completion Date

December 23, 2019

Completion Date

January 10, 2020

Last Updated

June 7, 2023

Enrollment

164

ACTUAL participants

Conditions

Idiopathic Parkinson Disease

Interventions

XADAGO (safinamide)

DRUG

A Study to Evaluate in Patients With Parkinsonian Type Disorders

NCT03683225

Idiopathic Parkinson Disease

View study

WITHDRAWNPHASE1

Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's

NCT05832775

Idiopathic Parkinson Disease

View study

COMPLETEDPHASE1/PHASE2

Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson

NCT05699161

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 7, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate in Patients With Parkinsonian Type Disorders

Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's

Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson

PA Behavior and HRQoL in Parkinson's Disease Patients Patients: Role of Social Cognitive Variables

An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)